World Health Organization site
Skip Navigation Links

Main
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 17 October 2012
Main ID:  NCT01097447
Date of registration: 25/03/2010
Primary sponsor: Innovative Medical
Public title: Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)
Scientific title: Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Date of first enrolment: December 2009
Target sample size: 500
Recruitment status: Recruiting
URL:  http://clinicaltrials.gov/show/NCT01097447
Study type:  Observational
Study design:  Observational Model: Cohort, Time Perspective: Prospective  
Countries of recruitment
United States
Contacts
Name:   Jenna Piel
Address: 
Telephone: 951-653-5566
Email:
Affiliation: 
Name:   Jenna Piel
Address: 
Telephone: 951-653-5566
Email: j.piel@imedsonline.com
Affiliation: 
Name:   Parag Majmudar, MD
Address: 
Telephone:
Email:
Affiliation:  Chicago Cornea Consultants, LTD
Name:   Sandy Feldman, M.D
Address: 
Telephone:
Email:
Affiliation:  Clear View Eye & Laser Medical Center
Name:   Bradley Bowman, M.D
Address: 
Telephone:
Email:
Affiliation:  Cornea Associates of Texas
Name:   Lance Forstot, MD
Address: 
Telephone:
Email:
Affiliation:  Corneal Consultants of Colorado, P.C
Name:   David Wallace, MD
Address: 
Telephone:
Email:
Affiliation:  LA Sight
Key inclusion & exclusion criteria

Inclusion Criteria:

- 8 years of age or older

- Diagnosis of keratoconus, post-LASIK ectasia, or pellucid marginal degeneration or
forme fruste pellucid marginal degeneration.

- Diagnosis of FFKC

- History of Radial Keratotomy with fluctuating vision.

- Ability to provide written informed consent

- Likely to complete all study visits

- Minimum corneal thickness of at least 300 measured by ultrasound or Pentacam

Exclusion Criteria:

- Severe corneal scarring that markedly affects vision

- Contraindications to any study medications or their components

- Pregnancy or breast feeding

- Active Herpes Corneal Disease



Age minimum: 8 Years
Age maximum: N/A
Gender: Both
Health Condition(s) or Problem(s) studied
Degeneration
Ectasia
Keratoconus
Intervention(s)
Primary Outcome(s)
Increase the biomechanical and biochemical stability of the cornea by inducing additional cross-links within [Time Frame: 1 year]
Secondary Outcome(s)
increase the biomechanical and biochemical stability of the cornea between collagen fibers using UVA light and the photo- mediator riboflavin [Time Frame: 1 year]
Secondary ID(s)
CXL (2)
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history